Figure 1. Anti-CD2 treatment pharmacodynamics, and CD2 expression on untreated freshly isolated lymphocytes.

A) WBC counts in all treated animals, groups A-C (n.s.). B, C) Showing treatment impact on hematocrit (Hct%) or platelet levels (n.s.). D) ALT and AST levels pre- and post-anti-CD2 infusion, group A. E, F) Post-treatment levels of leukocyte subsets. G) Showing bimodal CD2 and CD3 T cell expression in naïve cynomolgus monkeys, with memory cells having a higher CD2^hi and CD3^lo expression. Shown is a representative gate defining the bimodal distribution, and the three subsets of T cells (T_N, T_EM, T_CM) gated for CD2 and CD3. Predominantly, TN are CD3^hiCD2^lo and memory cells CD3^loCD2^hi. CCR7/CD45RA gating step not shown. H) Average median fluorescence intensities (MFI) of cell surface CD2 on CD4⁺-, CD8⁺-, NK-, B-, and regulatory T cells from naïve animals (n=4). I) Showing partial competitive binding of RH-CD2 and CD2-BV786 antibodies. J, K) RH-CD2 effectively depletes memory cells, while relatively sparing naïve lymphocytes in group A. L) Illustrating the CD8/CD4 ratio before and after RH-CD2 in group A. M) Showing a 695% CD25^hiFoxP3⁺ cell enrichment from day 0 to day 7 after RH-CD2 infusion (p=0.052) in group A. Data is presented as average (±SEM). Abbreviations: WBC, white blood cell count; CD, cluster of differentiation; CM, central memory; EM, effector memory; NK cell, natural killer cell.